Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Pulmatrix Corporate Overview (2018.08) – final for website
Related Articles
Trendlines Group, Ltd. (OTC: TRNLY) Delivering 10X returns on Israeli medical and agricultural innovation
Trendlines Group, Ltd. (OTC: TRNLY) (Singapore: 42T), interview with co-CEO/Chairman Steve Rhodes, discussing the company’s investment strategy in early-stage medical and agricultural innovation companies in Israel and Singapore. Since […]
CytoDyn (OTC: CYDY) Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV
VANCOUVER, Washington and NEW YORK, Dec 17, 2019 – In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone […]
CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test
CytoDyn Signs Non-binding Agreement for Diagnostic Licenseand Supply Agreement with IncellDX for PA-14 and/or PRO 140 (non-commercial grade) Collaboration represents an immediate revenue opportunity as a diagnostic test for receptor occupancy and the existence of […]